June 12, 2025 03:00 PM EDTUpdated 05:17 PM
R&D
Pharma

No­vo Nordisk plans Phase 3 tri­als of oral, in­jectable amy­cretin for ear­ly 2026

Kyle LaHucik

Biotech Correspondent

No­vo Nordisk plans to go straight to Phase 3 with its ex­per­i­men­tal weight loss drug amy­cretin in the first quar­ter of 2026, the Dan­ish drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

RFK Jr. names eight new ACIP mem­bers, in­clud­ing pop­u­lar vac­cine crit­ic Robert Mal­one

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

Have sky-high sales pro­jec­tions set the obe­si­ty mar­ket up to fail?

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times